

Editorial Reflections on the First Year of *Molecular Pharmaceutics*

In reflecting on the first year of publication of *Molecular Pharmaceutics*, several aspects stand out. First is the tremendous support for *Molecular Pharmaceutics* in the scientific community. We have hit all of our 2004 targets for the journal. This reflects the outstanding acceptance of *Molecular Pharmaceutics* in the scientific community through the submission of manuscripts, the highest quality and responsiveness of the reviewers, and the professionalism of the ACS Publications Division. The editorial process of receiving manuscripts, through review and publishing online and in print for *Molecular Pharmaceutics*, has been outstanding. The average receipt-to-Web publication time has been 11 weeks and the receipt-to-print time 17 weeks.

Several features of *Molecular Pharmaceutics* have been viewed very positively by the authors. One is the quality of graphics, and in particular, that there is no cost for publishing graphics in color in *Molecular Pharmaceutics*. The second feature is the graphic in the table of contents that helps draw attention to the content of a particular journal article. We view color figures as increasingly important in communicating the information content of research results today. Given the multifactor analysis required to interpret the complex and extensive data sets that are developed with today's innovative technologies and bioinformatic techniques, color is essential to communicating research results. Most importantly, manuscripts accepted for publication in *Molecular Pharmaceutics* immediately reach the worldwide scientific audience as part of the ACS family of journals and rapid publication on the Web.

During the next year we will introduce a new feature, "Brief Articles", that we believe will enhance the value of *Molecular Pharmaceutics* to the scientific community. Brief Articles describe a completed piece of work, but of a smaller scope than "Articles". See the Guidelines for Authors in this issue for a fuller definition of the scope of this manuscript format. In addition, we will begin inviting guest editors to assemble a "Featured Topic" section. A Featured Topic will be a scientific area of particular interest to the *Molecular Pharmaceutics* audience and will consist of approximately three to five papers on a chosen topic. This feature, implemented over the next two years, will not delay the publication of a submitted manuscript.

If you are interested in serving as a guest editor for a Featured Topic issue of *Molecular Pharmaceutics*, please contact the editorial office. We welcome input from authors on any topic you think of particular interest to our readers. Our goal is to meet the scientific publishing needs of the scientific community of *Molecular Pharmaceutics*. We again thank you the authors, reviewers, and audience for your outstanding support in 2004, and look forward to working with you in 2005 to make *Molecular Pharmaceutics* a leader in the publication of cutting edge research in the pharmaceutical sciences.

Gordon L. Amidon
Editor-in-Chief

MP040012H